INTRODUCTION: The aim of this international collaborative effort was to report 36-month longitudinal changes using the 6MWT in ambulant patients affected by Duchenne muscular dystrophy amenable to skip exons 44, 45, 51 or 53. MATERIALS AND METHODS: Of the 92 patients included in the study, 24 had deletions amenable to skip exon 44, 27 exon 45, 18 exon 51, and 28 exon 53. Five patients with a single deletion of exon 52 were counted in both subgroups skipping exon 51 and 53. RESULTS: The difference between subgroups amenable to skip different exons was not significant at 12 months but became significant at both 24 (p≤0.05) and 36 months (p≤0.01). DISCUSSION: Mutations amenable to skip exon 53 had lower baseline values and more ne...
Antisense oligonucleotide (AON)-mediated exon skipping is an emerging therapeutic for individuals wi...
International audienceBackground: Exon skipping therapy is an emerging approach in Duchenne Muscular...
Novel emerging therapies for Duchenne muscular dystrophy (DMD), such as antisense oligomer (AO) medi...
INTRODUCTION: The aim of this international collaborative effort was to report 36-month longitudina...
Introduction The aim of this international collaborative effort was to report 36-month longitudinal ...
IntroductionThe aim of this study was to report 36-month longitudinal changes using the North Star A...
Introduction The aim of this study was to report 36-month longitudinal changes using the North Star ...
Objective:To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations ...
In the last few years some of the therapeutical approaches for Duchenne muscular dystrophy (DMD) are...
OBJECTIVE: In the last few years some of the therapeutical approaches for Duchenne muscular dyst...
Abstract. Duchenne muscular dystrophy has a severe disease course, though variability exists. Case r...
Background: Exon skipping therapy is an emerging approach in Duchenne Muscular Dystrophy (DMD). Anti...
Antisense oligonucleotide (AON)-mediated exon skipping is an emerging therapeutic for individuals wi...
International audienceBackground: Exon skipping therapy is an emerging approach in Duchenne Muscular...
Novel emerging therapies for Duchenne muscular dystrophy (DMD), such as antisense oligomer (AO) medi...
INTRODUCTION: The aim of this international collaborative effort was to report 36-month longitudina...
Introduction The aim of this international collaborative effort was to report 36-month longitudinal ...
IntroductionThe aim of this study was to report 36-month longitudinal changes using the North Star A...
Introduction The aim of this study was to report 36-month longitudinal changes using the North Star ...
Objective:To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations ...
In the last few years some of the therapeutical approaches for Duchenne muscular dystrophy (DMD) are...
OBJECTIVE: In the last few years some of the therapeutical approaches for Duchenne muscular dyst...
Abstract. Duchenne muscular dystrophy has a severe disease course, though variability exists. Case r...
Background: Exon skipping therapy is an emerging approach in Duchenne Muscular Dystrophy (DMD). Anti...
Antisense oligonucleotide (AON)-mediated exon skipping is an emerging therapeutic for individuals wi...
International audienceBackground: Exon skipping therapy is an emerging approach in Duchenne Muscular...
Novel emerging therapies for Duchenne muscular dystrophy (DMD), such as antisense oligomer (AO) medi...